Lawmakers in New York have voted to legalize an adult-use cannabis market across the state.
AOAC International is now inviting submissions from cannabis laboratories with unique methods for mycotoxin screening and for the detection of Shiga toxin-producing Escherichia coli in cannabis plant materials and derivatives.
The International Association for the Study of Pain says it cannot currently endorse the general use of cannabis and cannabinoids for pain relief based on a lack of high-quality evidence.
California’s Honest Globe, Inc. and Michigan’s BioLyte Laboratories, LLC, have become the latest in a long line of companies to receive official warning letters from the FDA for the illegal marketing of unapproved CBD-containing drugs.
The majority of people with Parkinson’s disease in the United States have not used cannabis to treat their symptoms due to a lack of scientific evidence about its effectiveness, the researchers found.
N,N-dimethyltryptamine (DMT) is a psychedelic compound under investigation for a range of therapeutic uses. One avenue of research is being pursued by Algernon Pharmaceuticals, who are investigating whether sub-hallucinogenic DMT doses could help to protect and repair the brain in the hours after a stroke.
A synthetic cannabinoid with similar properties to THC can effectively reduce essential tremor in mice, according to a new study from researchers.
The diluent thickener, which is thought to be the culprit behind the outbreak of vaping-related lung injuries seen in the United States in 2019, has been discovered in one of Europe’s most popular CBD vape products.
Given the sheer scale of the country’s CBD sector, it’s likely a THC limit will be drawn up at some point. But what should it be? Well, one group of leading CBD experts have an answer.